Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease

Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease
Araclon Biotech is launching a Phase 2 clinical trial evaluating its active immunotherapy, or vaccine, ABvac40 for Alzheimer’s disease, after receiving approval from the Spanish Agency of Medicinal Products and Medical Devices. The multi-center trial will include 22 European clinical facilities (18 centers in Spain, two in France, one in Sweden and one in Italy). A total of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. kourosh says:

    Great job!
    I hope the Vaccine stop the progression of disease in patients who are already suffering from mild dementia.

  2. Doogie Howser says:

    we need a global commitment of the people to force the health community and Big Pharma along with their sponsored politicians to release those who are making improvements, than continuing to allow doctors to deny the disease any real rememdies.

Leave a Comment

Your email address will not be published. Required fields are marked *